Echinacea / selectivity Cancer Research Results

Ech, Echinacea: Click to Expand ⟱
Features: Immune system
Echinacea may have immune-modulating properties, which could theoretically help the body fight cancer.

Echinacea — Echinacea is a heterogeneous botanical preparation derived mainly from Echinacea purpurea, Echinacea angustifolia, and/or Echinacea pallida, containing alkylamides, caffeic acid derivatives such as cichoric acid, polysaccharides, glycoproteins, flavonoids, and other phenolics. It is best classified as a botanical natural health product / dietary supplement with immunomodulatory and anti-inflammatory activity rather than as a defined anticancer drug. Its most defensible cancer-relevant identity is an immune-axis modulator with inconsistent direct tumor-cell cytotoxicity depending on species, plant part, extract chemistry, and concentration.
-concentration of cichoric acid used as quality marker.
-best form is: Echinacea purpurea fresh aerial herb expressed juice

Primary mechanisms (ranked):

  1. Innate immune activation through macrophage stimulation, cytokine modulation, and macrophage polarization, especially polysaccharide-driven effects.
  2. NK-cell and Th1-skewing immune support, with possible enhancement of immune surveillance in preclinical models.
  3. CB2-linked alkylamide signaling that can modulate inflammation and, in some cancer-cell models, contribute to apoptosis.
  4. Direct tumor-cell growth inhibition by phenolic-rich extracts or cichoric acid, including telomerase suppression, β-catenin downregulation, caspase-9/PARP activation, and apoptosis in selected in-vitro models.
  5. ROS-associated apoptotic stress in selected cancer-cell models, secondary and formulation-dependent rather than a universal core mechanism.
  6. Context-dependent inflammatory pathway modulation, including NF-κB/MAPK-related signaling, which may support immune activation in normal immune cells but may be undesirable if it supports tumor-promoting inflammation.

Bioavailability / PK relevance: Echinacea is not a single pharmacokinetic entity. Alkylamides are systemically absorbed after oral dosing and can appear in plasma rapidly, whereas higher-molecular-weight polysaccharides are more likely to act through mucosal, gut-associated, or ex-vivo immune interfaces rather than high systemic exposure. Phenolic constituents and cichoric acid have variable exposure and metabolism. Product standardization is a major constraint.

In-vitro vs systemic exposure relevance: Many direct cancer-cell studies use crude extracts or isolated constituents at concentrations that may exceed achievable systemic exposure after oral supplementation. Immune-cell effects may be more plausible at lower exposure or via mucosal immune signaling, but extrapolation to tumor control is uncertain. This is concentration-driven and formulation-driven, not a field-based modality.

Clinical evidence status: Cancer evidence is preclinical / adjunct-risk only. There is no validated human anticancer efficacy signal and no established role as cancer treatment, prevention, radiosensitizer, or chemosensitizer. Human clinical evidence is strongest for short-term upper-respiratory infection indications, not oncology. In cancer patients, the main clinical issue is interaction uncertainty, especially immune therapies, immunosuppressants, CYP3A4/P-gp substrate chemotherapy, allergy risk, and inconsistent supplement composition.


Echinacea Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Macrophage activation and M1 polarization ↓ tumor-supportive immune tolerance (model-dependent) ↑ macrophage activation, ↑ inflammatory cytokine signaling, ↑ tumoricidal phenotype R/G Immune surveillance modulation Most central cancer-relevant mechanism; mainly driven by polysaccharide-rich fractions and immune-cell models.
2 NK cell and Th1 immune surveillance ↓ tumor escape potential (indirect) ↑ NK activity, ↑ MHC II, ↑ Th1-type CD4 response (model-dependent) G Host immune activation Biologically plausible adjunct mechanism, but not validated as clinical anticancer efficacy.
3 CB2 alkylamide signaling ↑ apoptosis in selected models, ↓ viability (context-dependent) ↑ immunomodulation, ↓ excessive TNF-type inflammation (context-dependent) R/G Cannabinoid-receptor-linked immune and death signaling Relevant mainly to alkylamide-rich root preparations; species and extract chemistry strongly affect interpretation.
4 Cichoric acid and phenolic apoptosis axis ↓ proliferation, ↓ telomerase, ↓ β-catenin, ↑ caspase-9, ↑ PARP cleavage ↔ or protective in some nonmalignant models (model-dependent) G Direct cytotoxicity and apoptosis Seen mainly in colon and other cell-line studies; systemic translation is limited by exposure and extract variability.
5 Mitochondrial ROS increase ↑ ROS, ↑ sub-G1 fraction, ↑ caspase-3 activity (model-dependent) ↔ or mixed antioxidant and inflammatory effects R/G Secondary apoptotic stress Not a universal mechanism; appears in selected lung cancer cell models and may depend on extract fraction and concentration.
6 NF-κB and MAPK immune signaling ↔ mixed; possible ↓ survival signaling or ↑ inflammatory support depending on context ↑ immune activation or ↓ excessive inflammation depending on constituent and cell type R/G Context-dependent inflammatory pathway modulation Important but bidirectional. NF-κB activation in immune cells can support host defense, while chronic tumor NF-κB can support cancer progression.
7 Cancer cell proliferation risk ↑ proliferation reported in some cell lines (formulation-dependent) ↔ not clearly harmful in standard short-term use G Potential adverse tumor-context effect Some hydroethanolic preparations promoted growth of HeLa and cholangiocarcinoma-derived QBC-939 cells; this argues against broad anticancer generalization.
8 Clinical Translation Constraint ↔ no proven clinical anticancer efficacy ↑ allergy risk, ↑ interaction uncertainty, possible immune stimulation G Deployment limitation Major constraints are variable species and plant part, inconsistent constituent standardization, uncertain systemic exposure, CYP3A4/P-gp interaction concerns, immune therapy concerns, and lack of oncology RCT efficacy.

P: 0–30 min R: 30 min–3 hr G: >3 hr
selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Scientific Papers found: Click to Expand⟱
6617- Ech,    Echinacea Angustifolia DC Extract Induces Apoptosis and Cell Cycle Arrest and Synergizes with Paclitaxel in the MDA-MB-231 and MCF-7 Human Breast Cancer Cell Lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, Nor, MCF10
Dose↝, selectivity↑, TumCCA↑, Apoptosis↑, toxicity↓, ChemoSen↑, other↝, *antiOx↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 1,   selectivity↑, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: selectivity, selectivity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:215  Target#:1110  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page